0.00Open0.05Pre Close0 Volume6.41K Open Interest0.50Strike Price0.00Turnover0.00%IV-83.28%PremiumMay 16, 2025Expiry Date2.79Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma65.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
X4 Pharmaceuticals Stock Discussion
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Let them be a lesson: always look at the TAM for new drugs.
X4 Pharmaceuticals Secures Future with $102.8M War Chest and Global Expansion
As previously disclosed on a Current Report on Form 8-K filed by X4 Pharmaceuticals, Inc. (the “Company”), on August 13, 2024, the Company received a deficiency letter (the “Nasdaq Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 32 consecutive business days, the closing bid price of the Company’s shares of common stock, $0.001 par value per share (“Common Stock”), has not been maint...
Reduced TAM to about 500 patients in the US (still probably an over-estimate given its rarity) recently. 23-27% of sales face exposure to Rx tariffs. $112M C&E acts as an immediate buffer. Sales targets will likely be lower than projections.
No comment yet